Introduction to Imaging Brain Tumor Metabolism with Positron Emission Tomography (PET)

References

• Wagner H N, Jr, Conti P S. Advances in medical imaging for cancer diagnosis and treatment. Cancer 1991; 67: 1121–1128
   PubMed Web of Science ®Google Scholar
• Conti P S, Bading J R, Wong D F, et al. Positron emitting radiotracers: Potential aids in the diagnosis and management of neoplasms. Tumor Diagn Ther 1988; 9: 175–176
   Google Scholar
• Strauss L G, Conti P S. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623–648
   PubMed Web of Science ®Google Scholar
• DiChiro G, Dela Paz R L, Brooks R A, et al. Glucose utilization of cerebral gliomas measurement by [FJfluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323–1329
   PubMed Web of Science ®Google Scholar
• DiChiro G, Oldfield E, Bairamian D, . In vivo glucose utilization of tumors of the brain stem and spinal cord. Positron Emission Tomography, T Greitz, D H Ingvar, L Widen, et al. Raven Press, New York 1985; 351–361
   Google Scholar
• DiChiro G. Positron emission tomography using [18F]fluoro-deoxyglucose in brain tumors: A powerful diagnostic and prognostic tool. Invest Radiol 1986; 22: 360–371
   Web of Science ®Google Scholar
• DiChiro G, Oldfield E, Wright D C, et al. Cerebral necrosis after radiotherapy and for intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 1987; 8: 1083–1091
   Web of Science ®Google Scholar
• DiChiro G, Hathaway J, Katz D A, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and possibility of recurrence: A PET study. Radiology 1987; 164: 521–526
   PubMed Web of Science ®Google Scholar
• Patronas N J, DiChiro G, Brooks R A, et al. [18F] Fluoro-deoxyglucose and positron emission tomography in evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885–889
   PubMed Web of Science ®Google Scholar
• Patronas N J, DiChiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. Neurosurgery 1985; 62: 816–822
   Web of Science ®Google Scholar
• Mineura K, Yasuda T, Kowada M, et al. Positron emission tomographic evaluations in the diagnosis and therapy of multifocal glioblastoma. Pediatr Neurol 1985–1986; 12: 208–213
   Google Scholar
• Mineura K, Yasuada T, Kowada M, et al. Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral haemocirculation and metabolism in patients with gliomas. J Neuro-Oncol 1987; 5: 277–285
   PubMed Web of Science ®Google Scholar
• Mineura K, Suda Y, Yasuda T, et al. Early and late stage positron emission tomography (PET) studies on the haemocirculation and metabolism of seemingly normal brain tissue in patients with gliomas following radiochemotherapy. Acta Neurochem 1988; 93: 110–115
   PubMed Web of Science ®Google Scholar
• Mineura K, Yasuda T, Sasajima T, et al. Clinical significance of F-18 fluorodeoxyglucose positron emission tomography in brain tumors. European Workshop on FDG in Oncology, HeidelbergGermany June 15–16, 1990
   Google Scholar
• Kornblith P L, Cummins C J, Smith B H, et al. Correlation of experimental and clinical studies of metabolism by PET scanning. Prog Exp Tumor Res 1984; 27: 170–178
   PubMed Web of Science ®Google Scholar
• Brownell G L, Kariento A L, Swartz M, et al. PET in oncology: The Massachusetts General Hospital experience. Semin Nucl Med 1985; 15: 201–209
   PubMed Web of Science ®Google Scholar
• Hawkins R A, Phelps M E, Huang S C. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment: Studies in human brain tumors with PET. J Cereb Blood Flow Metab 1986; 6: 170–183
   PubMed Web of Science ®Google Scholar
• Doyle W K, Budinger T F, Valk P E, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F] FDG and f Rb] positron emission tomography. JCAT 1987; 11(4)563–570
   Google Scholar
• Tyler J L, Diksic M, Villemure J-G, et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 1987; 28: 1123–1133
   PubMed Web of Science ®Google Scholar
• Washington C, Tyler J L, Villemure J G. Stereotactic biospy and positron emission tomography correlation of cerebral gliomas. Surg Neurol 1987; 27: 87–92
   PubMedGoogle Scholar
• Alavi J B, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: A prediction of prognosis. Cancer 1988; 62: 1074–1078
   PubMed Web of Science ®Google Scholar
• Alavi A, Alavi J B, Lenkinski R E. Complementary roles of PET and MR spectroscopy in the management of brain tumors. Radiology 1990; 177: 617–618
   PubMed Web of Science ®Google Scholar
• Valk P E, Budinger T F, Levin V A, et al. PET of malignant cerebral tumors after interstitial brachytherapy: Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 1988; 69: 830–838
   PubMed Web of Science ®Google Scholar
• Kuwabara Y, Ichiya Y, Otsuka M, et al. High [l8F] FDG uptake in primary cerebral lymphoma: A PET study. JCAT 1988; 6: 47–48
   Google Scholar
• Rozental J M, Levine R L, Nickles R J, et al. Glucose uptake by gliomas after treatment. Arch Neurol 1989; 46: 1302–1307
   PubMed Web of Science ®Google Scholar
• Rozental J M, Levine R L, Nickles R J, et al. Cerebral diaschisis in patients with malignant glioma. J Neuro-Oncol 1990; 8: 153–161
   PubMed Web of Science ®Google Scholar
• Rozental J M. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) of brain tumors. Neurol Clin 1991; 9(2)287–305
   PubMed Web of Science ®Google Scholar
• Francavilla T L, Miletich R S, Dichiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1898; 24: 1–5
   Google Scholar
• Luyten P R, Marien Ad J H, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-l MR spectroscopic imaging and PET. Radiology 1990; 176: 791–799
   PubMed Web of Science ®Google Scholar
• Thomas D GT, Brooks D J, Beaney R P. Positron emission tomography in brain tumour imaging. Prog Exp Tumor Res 1985; 29: 50–56
   PubMed Web of Science ®Google Scholar
• Alger J R, Frank J A, Bizzi A, et al. Metabolism of human gliomas: Assessment with H-l MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990; 177: 633–641
   PubMed Web of Science ®Google Scholar
• Conti P S, Camargo E E, Grossman S A, et al. Multiple radiotracers for evaluation of intracranial mass lesions using PET. J Nucl Med 1991; 32: 954
   Google Scholar
• Kim C K, Alavi J B, Alavi A, et al. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neuro-Oncol 1991; 10: 85–91
   PubMed Web of Science ®Google Scholar
• Hanson M W, Glantz M J, Hoffman J M, et al. FDG-PET in selection of brain lesions for biospy. JCAT 1991; 15(5)796–801
   Google Scholar
• Glantz M, Hoffman J M, Coleman R E, et al. Identification of early recurrence of primary central nervous system tumors by [F] fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347–355
   PubMed Web of Science ®Google Scholar
• Ogawa T, Shishido F, Kanno I, et al. Values of PET for diagnosis of recurrent brain tumor and radiation necrosis. HeidelbergGermany June 15–16, 1990, European Workshop on FDG in Oncology
   Google Scholar
• Coleman R E, Hoffman J M, Hanson M W, et al. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991; 326: 616–622
   Google Scholar
• Schmall B, Conti P S, Kleinert E, Whitmore W F, Jr. Metabolic characterization of rat prostatic carcinoma in vivo with radiolabeled alpha-aminoisobutyric acid (AIB), aminocyclopenta-necarboxylic acid (ACPC), 2-deoxy-D-glucose (2-DG), and thymidine (TdR). Biochemistry 1983; 22(15)36A
   Google Scholar
• Schmall B, Conti P S, Kleinert E L, Schaeffer D. Tumor and organ biochemical profiles determined in vivo following uptake of a combination of radiolabeled substrates: Potential applications for PET. Am J Phys Imag 1992; 7: 2–11
   PubMedGoogle Scholar
• Gelbard A S, Benua R S, Laughlin J S, et al. Quantitative scanning of osteogenic sarcoma with nitrogen-13 labeled L-glutamate. J Nucl Med 1979; 20: 782–784
   PubMed Web of Science ®Google Scholar
• Hubner K F, Krauss S, Washburn L C, et al. Tumor detection with 1-aminocyclopentane and 1-aminocyclobutane C-U-car-Contiboxylic acids using positron emission computerized tomography. Clin Nucl Med 1981; 6: 249–252
   PubMedGoogle Scholar
• Hubner K F, Purvis J T, Mahaley S M, Jr, et al. Brain tumor imaging by positron emission computed tomography using C-11 labeled amino acids. JCAT 1982; 6: 544–550
   Google Scholar
• Hubner K F, Smith G T, Goodman M M, et al. Dynamic FDG and amino acid PET for assessment of tumor proliferation. European Workship on FDG in Oncology, HeidelbergGermany June 15–16, 1990
   Google Scholar
• Reiman R E, Rosen G, Gelbard A S, Benua R S, Laughlin J S. Imaging of primary Ewing sarcoma with N-13 L-glutamate. Radiology 1982; 142: 495–500
   PubMed Web of Science ®Google Scholar
• Yonekura Y, Benua R S, Brill A B, et al. Increased accumulation of 2-deoxy-2-[F]-fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133–1137
   PubMed Web of Science ®Google Scholar
• Conti P S, Kleinert E, Schmall B, et al. The Dunning R3327G prostatic adenocarcinoma tumor model: Tumor-localization of radiolabeled thymidine: A potential agent for imaging with PET. J Nucl Med 1983; 24(5)P40
   Google Scholar
• Conti P S, Schmall B, Kleinert E, et al. Chemotherapeutic-in-duced changes in the accumulation of radiolabeled thymidine (TdR), 2-deoxy-D-glucose (2-DG), and alpha-aminoisobutyric acid (AIB) in rat prostatic adenocarcinoma. Biochemistry 1984; 23: 3379
   Web of Science ®Google Scholar
• Conti P S, Kleinert E, Schmall B, et al. Potential use of carbon-11 labeled thymidine for studying the effect of therapy on prostatic adenocarcinoma in vivo. 32nd Meeting of the Radiation Research Society, Orlando, FL, March, 25–291984
   Google Scholar
• Conti P S, Kleinert E, Schmall B, et al. Comparative uptake studies of radiolabeled thymidine in the Dunning R3327G fast-growing and R3327H slow-growing prostatic adenocarcinoma in vivo. 79th Meeting of the American Urological Association, New Orleans, LA, May, 6–101984
   Google Scholar
• Conti P S, Grossman S A, Wilson A, et al. Laboratory and clinical imaging studies of primary brain tumors using C-ll thymidine and positron emission tomography. Annual Meeting American Society Clinical Oncologists, Washington, DC, May, 20–221990
   Google Scholar
• Conti P S, Grossman S A, Wilson A A, et al. Brain tumor imaging with C-ll labeled thymidine and PET. Radiology 1990; 177P: 234
   Google Scholar
• Schmall B, Conti P S, Bigler R E, et al. Imaging studies of patients with malignant fibrous histiocytoma using C-ll alpha-aminoisobutryric acid (AIB). Clin Nucl Med 1987; 1: 22–26
   Google Scholar
• Ginos J Z, Cooper A JL, Dhawan V, et al. [13N] Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987; 28: 1844
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Muhr C, Ericson K, et al. Normal pituitary examined with positron emission tomography and methyl-[11C]L-methionine and methyl-[11C]-D-methionine. Neuroradiology 1987; 29: 221–225
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Ericson K, Hagenfeldt L, et al. PET Study of methionine accumulation in glioma and normal brain tissue: Completion with branched chain amino acids. JCAT 1987; 11(2)208–213
   Google Scholar
• Bergstrom M, Muhr C, Lundberg P O, et al. Amino acid distribution and metabolism in pituitary adenomas using positron emission tomography with D-[C]methionine and L-[C]methi-onine. JCAT 1987; 11: 384–389
   Google Scholar
• Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988; 29: 1633–1637
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Matsuzawa T, Kubota K, et al. Relationship between histologic type of primary lung cancer and carbon-11 L-methionine uptake with positron emision tomography. J Nucl Med 1989; 30: 33–37
   PubMed Web of Science ®Google Scholar
• Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988; 29: 1521–1525
   PubMed Web of Science ®Google Scholar
• Minn H, Soini I. [F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61–66
   PubMedGoogle Scholar
• Strauss L G, Clorius J H, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329–332
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou A, Strauss L G, Clorius J H, et al. Studies with positron emission tomography after systemic administration of fluorine-18 uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993; 34: 1075–1981
   PubMed Web of Science ®Google Scholar
• Diksic M, Sako K, Feindel W, et al. Pharmacokinetics of positron-labeled 1,3-feis (2-chloroethyl) nitrosourea in human brain tumors using positron emission tomography. Cancer Res 1984; 44: 3120–3124
   PubMed Web of Science ®Google Scholar
• Mintun M A, Welch M J, Mathias C J, et al. Application of 16-alpha-[F] fluoro-17-beta estradiol for the assessment of estrogen receptors in human breast carcinoma. J Nucl Med 1987; 28: 320
   Google Scholar
• Mintun M A, Welch M J, Siegel B A, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45
   PubMed Web of Science ®Google Scholar
• Poste G, Greig R. On the genesis and regulation of cellular heterogeneity in malignant tumors. Invas Metas 1982; 2: 137–176
   PubMedGoogle Scholar
• Henson D E. Heterogeneity in tumors. Arch Pathol Lab Med 1982; 106: 597–598
   PubMed Web of Science ®Google Scholar
• Warburg O. The Metabolism of Tumors. Arnold Constable, London 1930; 75–327
   Google Scholar
• Johnstone R M, Scholefield P G. Amino acid transport in tumor cells. Adv Cancer Res 1965; 9: 143–226
   PubMedGoogle Scholar
• Foster D O, Pardee A B. Transport of amino acids by confluent and nonconfluent 3T3 and polyoma virus-transformed 3T3 cells growing on glass cover slips. J Biol Chem 1969; 244: 2675–2681
   PubMed Web of Science ®Google Scholar
• Isselbacher K J. Sugar and amino acid transport by cells in culture: Differences between normal and malignant cells. N Engl J Med 1972; 286: 929–933
   PubMed Web of Science ®Google Scholar
• Parnes J R, Isselbacher K J. Transport alternations in virus transformed cells. Prog Exp Tumor Res 1978; 22: 79–122
   PubMedGoogle Scholar
• Taylor J H, Woods P S, Hughes W L. The organization and duplication of chromosomes as revealed by autoradiographic studies using tritium labeled thymidine. Proc Natl Acad Sci USA 1957; 43: 122–127
   PubMed Web of Science ®Google Scholar
• Chang L O, Looney W B. A biochemical and autoradiographic study of the in vivo utilization of tritiated thymidine in regenerating rat liver. Cancer Res 1965; 25: 1817–1822
   PubMed Web of Science ®Google Scholar
• Steward P A, Quastler H, Skougaard M R, et al. Four-factor model analysis of thymidine incorporation into mouse DNA and the mechanism of radiation effects. Radiat Res 1965; 24: 521–537
   PubMed Web of Science ®Google Scholar
• Lea M A, Morris H P, Weber G. Comparative biochemistry of hepatomas. VI. Thymidine incorporation into DNA as a measure of hepatoma growth rate. Cancer Res 1966; 26: 465–469
   PubMed Web of Science ®Google Scholar
• Cleaver J E. Thymidine Metabolism and Cell Kinetics. North Holland, Amsterdam 1967
   Google Scholar
• Frindel E, Malaise F, Tubiana M. Cell proliferation kinetics in five human solid tumors. Cancer 1968; 22: 661–620
   Google Scholar
• Shapiro W R. The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors. Cancer Res 1972; 32: 2178–2185
   PubMed Web of Science ®Google Scholar
• Tew K D, Taylor D M. The relationship of thymidine metabolites to the use of functional incorporation as measure of DNA synthesis and tissue proliferation. Eur J Cancer 1978; 14: 153–168
   PubMed Web of Science ®Google Scholar
• Larson S M, Weiden P L, Granbaum Z, et al. Positron imaging feasibility studies. I. Characteristics of [H] thymidine uptake in rodent and canine neoplasm. Concise Communication. J Nucl Med 1981; 22: 869–874
   PubMed Web of Science ®Google Scholar
• Shields A F, Lim K, Grierson J, et al. Utilization of labeled thymidine in DNA synthesis: Studies for PET. J Nucl Med 1990; 31: 337–342
   PubMed Web of Science ®Google Scholar
• Volkow N, Goldman S S, Flam E S, et al. Labeled putrescine as a probe in brain tumors. Science 1983; 221: 673–675
   PubMed Web of Science ®Google Scholar
• Hiesiger E, Follwer J S, Wolf A P, et al. Serial PET studies of human cerebral malignancy with [1 - C]putrescine and [1- C]2-deoxy-D-glucose. J Nucl Med 1987; 28: 1251–1261
   PubMed Web of Science ®Google Scholar
• Sokoloff L, Reivich M, Kennedy C, et al. The [l4C] deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897–916
   PubMed Web of Science ®Google Scholar
• Phelps M E, Huang S C, Hoffman E J, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with [F-18] 2 fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979; 5: 371–388
   Google Scholar
• Reivich M, Kuhl D, Wolf A, et al. The [18F] fluorodeoxyglucose method for the measurement of the local cerebral glucose utilization in man. Circ Res 1979; 44: 127–137
   PubMed Web of Science ®Google Scholar
• Mazziotta J C, Phelps M E, Kuhl D E. Tomographic mapping of humans cerebral metabolism: Normal unstimulated state. Neurology 1981; 31: 503–516
   PubMed Web of Science ®Google Scholar
• Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1989; 36: 879–887
   Google Scholar
• Kuhl D E, Phelps M E, Selin C. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computer tomography of [18F]FDG and [13N]-NH3. Ann Neurol 1980; 8: 348–360
   PubMed Web of Science ®Google Scholar
• Buchsbaum M S, Gerner R, Post R M. The effects of sleep deprivation on average evoked responses in depressed patients and in normals. Biol Psychiatry 1981; 16(4)351–363
   PubMed Web of Science ®Google Scholar
• Heiss W D, Pawlik G, Herholz K, et al. Regional cerebral glucose metabolism in man during wakefulness, sleep, and dreaming. Brain Res 1985; 327: 362–366
   PubMed Web of Science ®Google Scholar
• Wu J, Buchsbaum M S, Gillin J C. PET Study of sleep deprivation. American Psychiatry Association, Chicago May 9–14, 1987
   Google Scholar
• Zanzonico P B, Bigler R E, Leonard R W, et al. The enzymatic basis of the biodistribution of FDG: Implications for tumor imaging. J Nucl Med 1985; 26: P64
   Google Scholar
• O'Tuama L A, Guilarte T R, Douglass K H, et al. Assessment of [C]-L-mefhionine transport into the human brain. J Cereb Blood Flow Metab 1988; 8: 341–345
   PubMed Web of Science ®Google Scholar
• Ericson K, Lilja A, Bergstrom M, et al. Positron emission tomography with 11-C-methyl-L-mefhionine, 11-C-D-glucose, and 68-Ga-EDTA in supratentorial tumors. JCAT 1985; 9: 683–689
   Google Scholar
• Lilja A., Bergstrom J, Hartvig P, et al. Dynamic study of supratentorial gliomas with L-methyl-[uC]-methionine and positron emission tomography. AJNR 1985; 6: 505–514
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Muhr C, Lundberg P O, et al. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: A PET study. JCAT 1987; 11: 815–819
   Google Scholar
• Reiman R E, Benua R S, Gelbard A S, et al. Imaging of brain tumors after administration of L-(N-13) glutamate. Concise Communcation. J Nucl Med 1982; 23(8)682–687
   PubMed Web of Science ®Google Scholar
• Weinhard K, Herholz K, Coenen H H, et al. Increased amino acid transport into brain tumors measured by PET of L-2-[18F]fluorotyrosine. J Nucl Med 1991; 32: 1338–1346
   PubMed Web of Science ®Google Scholar
• Katsuyoshi M, Kowada M, Shishido F. Brief Communication– Brain tumor imaging with synthesized [18F]-fluorophenylalanine and positron emission tomography. Surg Neurol 1989; 31: 468–469
   PubMed Web of Science ®Google Scholar
• Meyer G J, Harre R, Orth F, et al. In vivo protein synthesis in human brain tumors measured with 11C-l.-methionine. J Nucl Med 1989; 30: 910–911
   Google Scholar
• Hayes R L, Washburn L C, Wieland B W, et al. Carboxy-labeled C-11 1-aminocyclopentanecarboxylic acid, a potential agent for cancer detection. J Nucl Med 1976; 17: 748–751
   PubMed Web of Science ®Google Scholar
• Schmall B, Conti P S, Bigler R E, et al. Synthesis and quality assurance of C-l 1 alpha-aminoisobutyric acid (AIB), a potential radiotracer for imaging and amino acid transport studies in normal and malignant tissues. Int J Nucl Med Biol 1984; 3/4: 209–214
   Google Scholar
• Bigler R E, Zanzonico P B, Schmall B, et al. Preclinical evaluation of [11C]-alpha-aminoisobutyric acid (AIB) as a tumor-localizing radiotracer: Studies using the spontaneous canine tumor model. Eur J Nucl Med 1985; 10: 48–55
   PubMedGoogle Scholar
• Conti P S, Sordillo P P, Schmall B, et al. Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in a patient with advanced malignant melanoma. Eur J Nucl Med 1986; 12: 353–356
   PubMedGoogle Scholar
• Sordillo P P, DiResta G R, Fissekis J, et al. Tumor imaging with carbon-11 labeled alpha-aminoisobutyric acid (AIB) in patients with malignant melanoma. Am J Phys Imag 1991; 7: 2–11
   Google Scholar
• Hubner K F. Unnatural amino acids in PET oncology. 5th Annual Meeting of the Institute for Clinical PET, McLean, VA, October, 28–311993
   Google Scholar
• Shields A F, Graham M M, O'Sullivan F. Use of C-l 1 thymidine with PET and kinetic modeling to produce images of DNA synthesis. J Nucl Med 1992; 33: 1009–1010
   Google Scholar
• Thomas G, Szucs M, Mamone J Y, et al. Sigma and opioid receptors in human brain tumors. Life Sci 1990; 46: 1279–1286
   PubMed Web of Science ®Google Scholar
• Muhr C, Bergstrom M, Mundberg P O, et al. Dopamine receptors in pituitary adenomas: PET visualization. JCAT 1986; 10: 175–180
   Google Scholar
• Ter-Pogossian M M. Positron emission tomography instrumentation. Positron Emission Tomography, M Reivich, A Alavi. Alan R Liss, New York 1985; 43–61
   Google Scholar
• Woodard H Q, Bigler R E, Freed B, et al. Expression of tissue isotope distribution. J Nucl Med 1975; 16: 958–959
   PubMed Web of Science ®Google Scholar
• Reivich M, Alavi A, Wolf A, et al. Use of 2-deoxy-D-l-[nC] glucose for the determination of local cerebral glucose metabolism in humans: Variation within and between subjects. J Cereb Blood Flow Metab 1982; 2: 307–309
   PubMed Web of Science ®Google Scholar
• Grossman S A, Eller S, Dick J, et al. Thymidine, leucine, and 2-deoxyglucose incorporation in brain tumors and abscess: A quantitative autoradiographic (QAR) study with implications for PET scanning. Proc Annu Meet Am Assoc Cancer Res 1988; 29: 516
   Web of Science ®Google Scholar
• Mies G, Bodsch W, Paschen W, . Experimental application of triple labeled quantitative autoradiography for measurement of cerebral blood flow, glucose metabolism and protein biosynthesis. Positron Emission Tomography of the Brain, W D Heiss, M E Phelps, et al. Springer-Verlag, Berlin 1983; 19
   Google Scholar
• Kameyama M, Tsurumi Y, Shirane R, et al. Multiparametric analysis of brain tumor with PET. J Cereb Blood Flow Metab 1987; 7: S466
   Google Scholar
• Abe Y, Matsuzawa T, Itoh M, et al. Regional coupling of blood flow and methionine uptake in an experimental tumor assessed with autoradiography. Eur J Nucl Med 1988; 14: 388
   PubMedGoogle Scholar
• Meyer G J, Schober O, Gaab M R, . Multiparametric studies in brain tumors. Positron Emission Tomography in Clinical Research and Clinical Diagnosis, C Beckers, A Beckers, A Goffinet, et al. Kluwer Academy, Bol Dordrech 1989; 229
   Google Scholar
• Flier J, Mueckler M M, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492–1495
   PubMed Web of Science ®Google Scholar
• Persons D A, Schek N, Hall B L, et al. Increased expression of glycolysis-associated genes in oncogene-transformed and growth-accelerated states. Mol Carcinogen 1989; 2: 88–94
   PubMed Web of Science ®Google Scholar
• Federle M P. A radiologist looks at AIDS. Imaging evaluation based on symptoms complexes. Radiology 1988; 166: 553–562
   PubMed Web of Science ®Google Scholar
• Dubkin J F, Healton E B, Dickinson P CT, et al. Nonspecificity of ring enhancement in “medically cured” brain abscess. Neurology 1984; 34: 139–144
   PubMed Web of Science ®Google Scholar
• Levy R M, Rosenbloom S, Perret L V. Neurologic findings in AIDS: A review of 200 cases. AJR 1986; 147: 977–983
   PubMed Web of Science ®Google Scholar
• Moskowitz L B, Hensley G I, Chan J C, et al. The neuropathology of acquired immune deficiency syndrome. Arch Pathol Lab Med 1984; 108: 867–782
   PubMed Web of Science ®Google Scholar
• Lipkin W L, Parry G, Kiprov D, et al. Inflammatory neuropathy in homosexual men with lymphadenopathy. Neurology 1985; 35: 1479–1483
   PubMed Web of Science ®Google Scholar
• Elkin C M, Leon E, Grenell S L, et al. Intracranial lesions in the acquired immunodeficiency syndrome: Radiological (CT) features. JAMA 1985; 253: 393–396
   PubMed Web of Science ®Google Scholar
• Levy R M, Pons V G, Rosenblum M L. Central nervous system mass lesions in the acquired immunodeficiency syndrome (AIDS). J Neurosurg 1984; 61: 9–16
   PubMed Web of Science ®Google Scholar
• Summerfield G P. Demonstration of lesions of cerebral toxoplasmosis by computerized tomography. Postgrad Med J 1980; 56: 112–114
   PubMed Web of Science ®Google Scholar
• Levy R M, Bredesan E E, Rosenblum M L. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. J Neurosurg 1985; 62: 475–495
   PubMed Web of Science ®Google Scholar
• Navia B A, Cho E S, Petito C H, et al. The AIDS dementia complex. I. Clinical features. Ann Neurol 1986; 19: 517–524
   PubMed Web of Science ®Google Scholar
• Navia B A, Petito C K, Gold J WM, et al. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: Clinical and neuropathological findings in 27 patients. Ann Neurol 1986; 19: 224–238
   PubMed Web of Science ®Google Scholar
• Tadmor R, Davis K R, Robertson G H, et al. Computed tomography in primary malignant lymphoma of the brain. JCAT 1978; 2: 135–140
   Google Scholar
• Kazner E, Wilske J, Steinhoff H, et al. Computer assisted tomography in primary malignant lymphomas of the brain. JCAT 1978; 2: 125–134
   Google Scholar
• Petito C L, Cho E S, Lemann W, et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): An autopsy review. J Neuropathol Exp Neurol 1986; 45: 635–646
   PubMed Web of Science ®Google Scholar
• Zee C S, Segal H G, Rogers, et al. MR imaging of cerebral toxoplasmosis: Correlation of computed tomography and pathology. JCAT 1985; 9: 797–799
   Google Scholar
• Lee Y Y, Bruner J M, Von Tassel P, et al. Primary central nervous system lymphoma: CT and pathologic correlation. AJR 1986; 147: 747–752
   PubMed Web of Science ®Google Scholar
• Jack C R, Jr, Reese D F, Scherthauer B W. Radiographic findings in 32 years of primary CNS lymphoma. AJR 1986; 146: 271–276
   PubMed Web of Science ®Google Scholar
• Vietzke W M, Gelderman A H, Grimley P M, et al. Toxoplasmosis complicating malignancy: Experience at the National Cancer Institute. Cancer 1968; 21: 816–827
   PubMed Web of Science ®Google Scholar
• Whelan M A, Krichett I I, Handler M, et al. Acquired immunodeficiency syndrome: Spectrum of diseases and optimal contrast enhancement technique. AJR 1985; 145: 929–940
   PubMed Web of Science ®Google Scholar
• Hoffman J M, Waskin H A, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34: 567–575
   PubMed Web of Science ®Google Scholar
• Perlman M F, Conti P S, Schmall B, et al. Synthesis and purification of the antiviral agent l-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) labeled with iodine-125. Int J Nucl Med Biol 1984; 11: 215–218
   PubMedGoogle Scholar
• Sundoro-Wu B M, Schmall B, Conti P S, et al. Selective alkylation suitable for labeling the antiviral agent 2′-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) with carbon-11 for use in in vivo imaging. 187th National Meeting of the American Chemical Society, St. Louis, MO, April, 8–131984
   Google Scholar
• Wilson A A, Conti P S, Dannals R F, et al. Radiosynthesis of [q-N-methylacyclovir. J Lab Comp Radiopharm 1991; 29: 765–768
   Web of Science ®Google Scholar
• Alauddin M M, Conti P S, Mazza S M, et al. A novel synthesis suitable for labeling the antiviral agent 9-[3-fluoro-l-hydroxy-2-propoxy)methyl] guanine (FHPG) with F-18 for in vivo imaging by positron emission tomography. 206th Meeting of the American Chemical Society, Chicago, August, 22–261993
   Google Scholar
• Conti P S, Keppler J, Halls J M. Positon emission tomography: A financial and operational analysis. AJR 1994; 162: 1279–1286
   PubMed Web of Science ®Google Scholar